

O ADVENTO DO FIM DA FRAÇÃO DE EJEÇÃO?


### TERAPÊUTICAS INDEPENDENTES DA FRAÇÃO DE EJEÇÃO

ANTAGONISTAS DOS RECETORES DOS MINERALOCORTICÓIDES NÃO ESTEROIDES?

DISCLOSURES Consultancy fees, grants and speaker's honoraria from Astra Zeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk Roche, Sanofi, Servier, CSLVifor.

> Cândida Fonseca MD, PhD Heart Failure Clinic, Hospital S. Francisco Xavier/ULSLO Heart Failure Programme Hospital Luz Lisboa NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa. Portugal

# **Steroidal MRAs**: a pillar of guidelinedirected medical therapy for patients with **HF with reduced ejection fraction**



Zannad F, et al. N Engl J Med. 2011;364:11-21.

Advances

Class


ΙΑ

Failure






### Early RCTs in patients with HFpEF provided minimal support for use of various agents






#### TOPCAT: A tale of two populations Missed Primary Endpoint in HFpEF but **Suggestive of Benefit in Some Patients** Concern in patients with worse renal function



MR overactivation is a key driver of the vicious cycle of heart and kidney diseases, including CKD and HF


Advances



CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; MR, mineralocorticoid receptor. 1. Savarese G et al. *Diabetologia* 2024;67:246–262; 2. Epstein M, et al. *Am J Kidney Dis* 2022;80:658-666; 3. Gorini S, et al. *Front Endocrinol (Lausanne)* 2019;10:584; 4. Jia G, et al. *Hypertension* 2018;72;537–548; 5. Gomez-Sanchez E & Gomez-Sanchez CE. *Compr Physiol* 2014;4:965–994; 6. van de Heijden CDCC, et al. *Cardiovasc Res* 2018;114:944–953; 7. Buonafine M, et al. *Am J Hypertens* 2018;31:1165–1174; 8. Barrera-Chimal J, et al. *Kidney Int* 2019;96:302–319; Chilton RJ & Silva-Cardoso J. *Cardivasc Endocrinol Metab* 2023;12(3):e0289; 10. Abassi Z, et al. *Front Cardiovasc Med* 2022;9:933215.



<sup>th</sup> Advances in Hear Failure 10 e 11 de Outubro



PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Spironolactone (Accessed Aug 2024); 6. NIH. https://drugs.ncats.io/substance/6995V82D0B (Accessed Aug 2024); 7. Daiichi Sankyo Launches "MINNEBRO® Tablets" in Japan. Press Release 2019; 8. Ito S, et al. Hypertension 2020;75:51-58; 9. Lam C, et al. Eur J Heart Fail 2024;doi:10.1002/ejhf.3294; 10. Kolkhof P, et al. Pharmacol Res 2021:172:105859; 11. Novo Nordisk Press Release.

and key

studies

First

launch

https://www.novonordisk.com/news-and-ir-materials/news-details.html?id=168529 (Accessed Aug 2024); 12. Marx N, et al. Eur Heart J 2023;00:1-98; 13. Solomon S, et al. NEJM 2024 [in press]; 14. Vaduganathan M, et al. Nat Med 2024 [in press]; 15. Georgianos PI, et al. Am J Hypertens 2023;36:135-143; 16. Kerendia. PI.




Finerenone is a potent, highly selective **non-steroidal MRA** with Equivalent Heart: Kidney Tissue Distribution and **Potential Safety Advantages over steroidal MRAs** 

	Spironolactone	Eplerenone	Finerenone
MRA Class	Steroidal	Steroidal	Non- steroidal
Potency	High	Low	High
Selectivity	Low	Medium	High
Metabolites	Multiple, active	No active	No active
Tissue distribution	Kidney>>heart (>6-fold)	Kidney>heart (~3-fold)	Equivalent (1:1)


More selective for MR receptor than spironolactone or eplerenoneHighly potente

•More balanced Heart/Kidney Distribution than steroidal MRAs



Kolkhof P, NowackC, EitnerF.Curr OpinNephrolHypertens.2015;24:417-424

### FINEARTS-HF evaluated the efficacy and safety of finerenone in patients with HF LVEF ≥40%<sup>1</sup>



• SBP ≥160 mmHg‡

Finerenone is indicated for the treatment of chronic kidney disease (with albuminuria) associated with T2D in adults.<sup>4</sup> For prescribing information please refer to the SmPC of the product applicable in your country. Finerenone is not indicated for the treatment of heart failure. 40 mg od is not a licensed dosage of finerenone.

NT-proBNP  $\geq$ 900 pg/mL or BNP  $\geq$ 300 pg/mL (atrial fibrillation)

\*6016 randomized, 6001 included in efficacy analysis<sup>1</sup>; <sup>†</sup>Worsening HF events defined as either an unplanned HHF or an urgent heart failure visit; <sup>‡</sup>If not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments.

BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; HHF, hospitalization for heart failure; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association; od, once daily; PCI, percutaneous coronary intervention; R, randomisation; SBP, systolic blood pressure; TIA, transient ischemic attack; T2D, type 2 diabetes. 1. Solomon S, et al. *NEJM* 2024 [in press]; 2. Solomon S, et al. *NEJM* 2024 [in press] (Suppl 1); 3. Bayer AG. <a href="https://clinicaltrials.gov/ct2/show/NCT04435626">https://clinicaltrials.gov/ct2/show/NCT04435626</a> [accessed August 2024]; 4. Bayer AG. <a href="https://clinicaltrials.gov/ct2/show/NCT04435626">KERENDIA® (finerenone) Summary of Product Characteristics. 2023. https://www.ema.europa.eu/documents/product-information/kerendia-epar-product-information\_en.pdf</a> [accessed August 2024].



th Advances

Failure




The NEW ENGLAND JOURNAL of MEDICINE 2024

#### **ORIGINAL ARTICLE**

### Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S.D. Solomon, J.J.V. McMurray, M. Vaduganathan, B. Claggett, P.S. Jhund,
A.S. Desai, A.D. Henderson, C.S.P. Lam, B. Pitt, M. Senni, S.J. Shah, A.A. Voors,
F. Zannad, I.Z. Abidin, M.A. Alcocer-Gamba, J.J. Atherton, J. Bauersachs,
M. Chang-Sheng, C.-E. Chiang, O. Chioncel, V. Chopra, J. Comin-Colet,
G. Filippatos, C. Fonseca, G. Gajos, S. Goland, E. Goncalvesova, S. Kang,
T. Katova, M.N. Kosiborod, G. Latkovskis, A.P.-W. Lee, G.C.M. Linssen,
G. Llamas-Esperón, V. Mareev, F.A. Martinez, V. Melenovský, B. Merkely,
S. Nodari, M.C. Petrie, C.I. Saldarriaga, J.F.K. Saraiva, N. Sato, M. Schou,
K. Sharma, R. Troughton, J.A. Udell, H. Ukkonen, O. Vardeny, S. Verma,
D. von Lewinski, L. Voronkov, M.B. Yilmaz, S. Zieroth, J. Lay-Flurrie,
I. van Gameren, F. Amarante, P. Kolkhof, and P. Viswanathan,
for the FINEARTS-HF Committees and Investigators\*







### **Baseline Characteristics - FINEARTS-HF and other HFpEF trials**

		CHARM Preserved (n=3023)	EMPEROR Preserved (n=5988)	PARAGON-HF (n=4822)	TOPCAT (n=3445)	DELIVER HF (N=6263)	<mark>⊙ FINEARTS</mark> -H (N=6014)
	Age (years)	67±11	72±9	73±8	69±10	72±10	71±12
	Women (%)	40	45	52	52	44	45
	NYHA II (%)	61	82	72	63	75	69
-	NYHA III (%)	38	18	27	33	25	30
	NYHA IV (%)	2	0.3	0.6	<1	0.3	0.7
,	LVEF (%)	54±9	54±9	58±8	57±7	54±9	53±8
	Hypertension (%)	64	90	96	91	89	89
<b>_</b>	Diabetes (%)	28	49	43	32	45	41
	Hx of MI (%)	44	29	23	26	26	26
	Hx of AF (%)	29	52	52	35	56	55
	Stroke (%)	9	10	10	8	9	14
	eline NT-proBNP og/mL) – median	NA	971 (499-1740)	885 (863-908)	950 (588-192	0) 1011 (623-1751	) 1502
	eGFR (mL/min)	NA	61±20	63±19	68±20	61±19	62±20

20103 - Small SC meeting - 08 March 202


Date snapshot: 08 Mar 2023 Source: J-Review





## The **FINEARTS-HF** patient population was largely consistent with other contemporary HF trials, but patients had **more acute HF**

In FINEARTS-HF, 20% of participants were randomized during or within 7 days of a worsening HF event **Randomization timing relative to the most recent** worsening HF event Percentage of patients (%) Placebo (n=2998) Finerenone (n=3003) 20.3%; 20.3%; n=609 n=610 46.4%; 45.4%; n=1390 n=1364 34.3%; 33.3%; n=1030 n=998 >7 days to 3 months ≤7 davs >3 months or no prior worsening HF




Background medication use was robust and consistent between

treatment arms

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; GLP-1, glucagon-like peptide 1; HF, heart failure; SGLT-2i, sodium-glucose cotransporter-2 inhibitor. Solomon S. et al. *NEJM* 2024 [in press].



Finerenone demonstrated a clinically meaningful 16% relative risk reduction in the composite of CV deaths and total HF events





Tth Advances





### The statistically significant reduction in the composite CV outcome was driven by a reduction in HF events

#### Primary endpoint: Components of composite CV outcome

Outcome	Finerenone (N=3003)	Placebo (N=2998)	Ratio or difference (95% CI)		p-value
	n	n			
Composite CV outcome	1083	1283		RR=0.84 (0.74–0.95)	0.007
Total (first and recurrent) HF events*	842	1024		RR=0.82 (0.71–0.94)	0.006
CV death	242	260		HR=0.93 (0.78–1.11)	NR
			0.5 1	2	
		Γονουκ	finoronono	Favoura placebo	

Favours finerenone Favours placebo

\*One patient in each group was reported as having a HF event on the same day as a CV death and was counted as only one composite event in the primary analysis. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; NR, not reported; RR, rate ratio.

Solomon S, et al. NEJIM 2024 [in press].



	Finerenone	Placebo		
Category	Events <sup>1</sup>	Events <sup>1</sup>	RR (95% CI) <sup>1</sup>	
LVEF				
<60%	877	1061		0.82 (0.71–0.94)
≥60%	206	222	<b>⊢</b> →	0.94 (0.70–1.26)
SGLT-2i				
Yes	176	234	<b>⊢</b>	0.83 (0.60–1.16)
No	907	1049	<b>⊢</b>	0.85 (0.74–0.98)
			0.5	1 2
			Favours finerenone	Favours placebo

Rate ratios for the primary endpoint across all 17 pre-specified subgroups were in favour of finerenone and there were no significant interaction p-values<sup>1,2</sup>

CI, confidence interval; LVEF, left ventricular ejection fraction; RR, rate ratios; SGLT-2i, sodium-glucose cotransporter-2 inhibitors. 1. Solomon S, et al. *NEJM* 2024 [in press]; 2. Solomon S, et al. ESC 2024. Hot Line Presentation 7.



## Finerenone demonstrated significant benefits in the secondary efficacy endpoints of total HF events and patient-reported health status

**Secondary endpoints** 

Outcome		Finerenone (n=3003)	Placebo (n=2998)	Ratio or Difference (95% Cl)	p-value
		n	n		
Total (first and recurrent) HF events*		842	1024	RR: 0.82 (0.71–0.94)	0.006
<b>Change in KCCQ-TSS</b> LS mean (SE)		8.0 (0.32)	6.4 (0.32)	Difference: 1.6 (0.8–2.3)	<0.001
Improvement in NYHA class from baseline to month 12 <sup>†</sup>	•	557 <sup>‡</sup> (18.6%)	553 (18.4%)	OR: 1.01 (0.88–1.15)	Testing hierarchy stops
Composite kidney outcome <sup>†</sup>		75 (2.5%)	55 (1.8%)	HR 1.33 (0.94–1.89)	Not applicable
All-cause death <sup>†</sup>		491 (16.4%)	522 (17.4%)	HR 0.93 (0.83–1.06)	All-cause death was tested outside hierarchy

\*One patient in each group was reported as having a HF event on the same day as a CV death and was counted as only one composite event in the primary analysis.<sup>†</sup>The secondary hypotheses were tested hierarchically as follows based on the rejection of the primary null hypothesis: total HF events; KCCQ total symptom score improvement and NYHA class improvement; and the composite kidney endpoint. All-cause death was tested outside this hierarchy, if the primary null hypothesis was rejected, at a nominal two-sided significance level of 5%. <sup>‡</sup>Result based on n=3002.



Tth Advances

Failure

CI, confidence interval; HF, heart failure; HR, hazard ratio; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score;



The overall incidence of **serious AEs was similar** between the finerenone and placebo groups

	Finerenone (N=2993)	Placebo (N=2993)			
Type of treatment-emergent safety outcome	n (%)	n (%)			
Any SAE	1157 (38.7%)	1213 (40.5%)			
20.4% and 20.6% of patients receiving finerenone and placebo respectively, discontinued the trial drug for reasons other than death					



## Finerenone increased the risk of manageable hyperkalemia and the incidence of hypokalemia was numerically lower compared to placebo

	Finerenone (N=2993)	Placebo (N=2993)
Type of treatment-emergent safety outcome	n (%)	n (%)
Investigator-reported hyperkalemia	289 (9.7%)	125 (4.2%)
Leading to hospitalization	16 (0.5%)	6 (0.2%)
Leading to death	0 (0%)	0 (0%)
Serum potassium		
>5.5 mmol/l	413 (14.3%)	199 (6.9 %)
>6.0 mmol/l	86 (3.0%)	41 (1.4%)
<3.5 mmol/l	127 (4.4%)	281 (9.7%)
Systolic blood pressure <100 mmHg	538 (18.5%)	361 (12.4%)

Hypokalemia (serum potassium <3.5 mmol/l) incidence was numerically lower for finerenone compared to placebo

K+

Advances

Failure

FINEARTS-HF was the first trial to include finerenone 40 mg dosing

**40 mg od is not a licensed dosage of finerenone, please consult local prescribing information for more detail.** Treatment emergent defined as all safety outcomes that occurred in patients who received at least one dose of study drug and up until 3 days following permanent discontinuation. eGFR, estimated glomerular filtration rate. Solomon S, et al. *NEJM* 2024 [in press].



**FINE-HEART was powered** to assess heart and kidney outcomes in patients with a high burden of CKM multimorbidity

Finerenone has been studied in RCTs of patients with T2D and CKD and separately in patients with HF (± T2D, ± kidney disease). Individually, these trials were not powered to evaluate treatment effects on CV death or efficacy in key subgroups<sup>1</sup>

ailure





FINE-HEART was able to more robustly assess the safety profile and efficacy of finerenone on CV death and other heart and kidney outcomes compared to the individual trials alone<sup>1</sup>

Finerenone is indicated for the treatment of chronic kidney disease (with albuminuria) associated with T2D in adults.2 For prescribing information please refer to the SmPC of the product applicable in your country. Finerenone is not indicated for the treatment of heart failure.

CKD, chronic kidney disease; CV, cardiovascular; HF, heart failure; RCT, randomized controlled trial; T2D, type 2 diabetes.

1. Vaduganathan M, et al. *Nat Med* 2024 [in press]; 2. Bayer AG. KERENDIA® (finerenone) Summary of Product Characteristics. 2023. https://www.ema.europa.eu/documents/product-information/kerendia-epar-product-information\_en.pdf [accessed August 2024].



### **FINE-HEART**: Finerenone was associated with significantly improved kidney outcomes compared to placebo

Outcome	Finerenone (n=9,501) n (%)	Placebo (n=9,490) n (%)		HR (95% CI)	p-value
Primary endpoint					
CV death (excluding unknown death)	421 (4.4)	471 (5.0)		0.89 (0.78–1.01)	0.076
Prespecified sensitivity analysis: CV death (including unknown death)	627 (6.6)	703 (7.4)		0.88 (0.79–0.98)	0.025
Secondary endpoints					
Kidney composite endpoint	557 (5.9)	685 (7.2)		0.80 (0.72–0.90)	<0.001
HHF	705 (7.4)	839 (8.8)		0.83 (0.75–0.92)	<0.001
CV death or HHF	1009 (10.6)	1168 (12.3)	⊢ <b>↓</b> ⊣	0.85 (0.78–0.93)	<0.001
New onset atrial fibrillation	286 (3.0)	345 (3.6)		0.83 (0.71–0.97)	0.018
Major adverse CV events	1428 (15.0)	1554 (16.4)	H I	0.91 (0.85–0.98)	0.010
All-cause death	1042 (11.0)	1136 (12.0)		0.91 (0.84–0.99)	0.027
All-cause hospitalization	4261 (44.8)	4401 (46.4)	•	0.95 (0.91–0.99)	0.025
All-cause death or all-cause hospitalization	4467 (47.0)	4653 (49.0)	•	0.94 (0.91–0.98)	0.007
			0.5 1	2	

CI, confidence interval; CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; HR, hazard ratio.

Favours finerenone Favours placebo



Vaduganathan M, et al. Nat Med 2024 [in press].



Finerenone demonstrated a statistically significant **16% relative risk reduction in the composite CV outcome** (number of CV deaths and HF events) in patients with **HF and LVEF ≥40%**, compared to placebo

The effects of finerenone on the CV composite outcome were **consistent across a broad population**, regardless of baseline use of an SGLT-2i or LVEF status

Finerenone demonstrated significant benefits in the secondary efficacy endpoints of total HF events and patient-reported health status

Finerenone was well tolerated, **confirming the well-known safety profile**, with a comparable incidence of treatment-emergent SAEs to placebo

CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; SAE, serious adverse event; SGLT-2i, sodium-glucose co-transporter-2 inhibitor. Solomon S, et al. *NEJM* 2024 [in press].





O ADVENTO DO FIM DA FRAÇÃO DE EJEÇÃO?

#### TERAPÊUTICAS INDEPENDENTES DA FRAÇÃO DE EJEÇÃO

#### ANTAGONISTAS DOS RECETORES MINERALOCORTICÓIDES NÃO ESTEROIDES?

### **Benefícios comprovados**:

- EFpEF / EFmrEF
- Veventos CV na DM2 e DRC

		HR (95% CI)
Composite outcome		0.86 (0.78–0.95)
CV death		0.88 (0.76–1.02)
Non-fatal MI		- 0.91 (0.74–1.12)
Non-fatal stroke	⊢∳	0.99 (0.82–1.21)
HF Hospitalization F	- <b>&gt;</b> '	0.78 (0.66–0.92)

- Sem evidencia (RCTs) na EFrEF
- Efeito de classe?
- FIEARTS-HF & Guidelines?